<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093415</url>
  </required_header>
  <id_info>
    <org_study_id>CRS00002743</org_study_id>
    <nct_id>NCT03093415</nct_id>
  </id_info>
  <brief_title>Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care</brief_title>
  <official_title>A Prospective Cohort Study Comparing the Effectiveness of Zepatier for the Treatment of Hepatitis C in an Academic Center Population to People Who Inject Drugs (PWIDs) in a Safety Net Clinic Setting Engaged in Either a Medication Assisted Therapy (MAT) or Syringe Exchange Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      hepatitis C virus (HCV) has traditionally been treated in subspecialty health centers given&#xD;
      the complexity of older pegylated interferon containing regimens, formerly the standard of&#xD;
      care. This model has persisted into the modern era of direct anti-viral agents (DAAs) despite&#xD;
      their relative simplicity, creating a bottleneck of human resources necessary to fight the&#xD;
      largest infectious epidemic in North America. In addition, stigma and fear over cost has lead&#xD;
      payers to restrict treatment in People Who Inject Drugs (PWIDs), even though a majority of&#xD;
      new infections occur in this population.&#xD;
&#xD;
      This study evaluates the effectiveness of treatment of HCV with elbasvir-grasoprevir in PWIDs&#xD;
      in a real world, community health clinic setting.&#xD;
&#xD;
      There are two prospective cohorts of PWIDs of 25 patients each, both in primary care-based&#xD;
      community health clinics in Portland, Oregon. Cohort one is actively engaged with ambulatory&#xD;
      medication assisted therapy with buprenorphine or extended released injectable naltrexone.&#xD;
      Cohort two maintains active injection drug use with needle exchange and risk reduction&#xD;
      education.&#xD;
&#xD;
      These groups are compared to a 50 patient retrospective cohort of people with substance use&#xD;
      disorders at tertiary care hepatology-based treatment program.&#xD;
&#xD;
      All patients have genotype 1 or 4 HCV and are treated with elbasvir-grasoprevir for 12 weeks.&#xD;
&#xD;
      The investigators hypothesize there is no difference in sustained viremic response at 12 or&#xD;
      48 weeks post-completion of treatment (SVR 12, 48) when treating patients in a community&#xD;
      health clinic setting as compared to the standard-of-care subspecialty setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C has traditionally been treated in subspecialty health centers given the&#xD;
      complexity of older pegylated interferon containing regimens, formerly the standard of care.&#xD;
      This model has persisted into the modern era of direct anti-viral agents (DAAs) despite their&#xD;
      relative simplicity, creating a bottleneck of human resources necessary to fight the largest&#xD;
      infectious epidemic in North America. In addition, stigma and fear over cost has lead payers&#xD;
      to restrict treatment in People Who Inject Drugs (PWIDs), even though a majority of new&#xD;
      infections occur in this population.&#xD;
&#xD;
      This study evaluates the effectiveness of treatment of hepatitis C virus (HCV) with&#xD;
      elbasvir-grasoprevir in people who inject drugs (PWIDs) in a real world, community health&#xD;
      clinic setting.&#xD;
&#xD;
      There are two prospective cohorts of PWIDs of 25 patients each, both in primary care-based&#xD;
      community health clinics in Portland, Oregon. Cohort one is actively engaged with ambulatory&#xD;
      medication assisted therapy with buprenorphine or extended released injectable naltrexone.&#xD;
      Cohort two maintains active injection drug use with needle exchange and risk reduction&#xD;
      education.&#xD;
&#xD;
      These groups are compared to a 50 patient retrospective cohort of people with substance use&#xD;
      disorders at tertiary care hepatology-based Academic Health Center.&#xD;
&#xD;
      All patients have genotype 1 or 4 HCV and are treated with elbasvir-grasoprevir for 12 weeks.&#xD;
      The investigators exclude patients who: are under the age of 18; have a history of liver&#xD;
      transplant; have failed past treatment of HCV; have an Aspartate aminotransferase Platelet&#xD;
      Ratio Index (APRI) &gt; 0.7 or APRI &gt;0.7 but fibrosure/fibroscan of F2 or less; patients with&#xD;
      genotype 1a and Nonstructural 5a (NS5a) resistance associated variants (RAVs); have clinical&#xD;
      or radiologic evidence of cirrhosis; have aminotransferase levels &gt;10x upper limit of normal;&#xD;
      have a hemoglobin of less than 11g/dL, and are co-infected with hepatitis B or HIV.&#xD;
&#xD;
      The investigators hypothesize there is no difference in sustained viremic response at 12 or&#xD;
      48 weeks post-completion treatment (SVR 12, 48) when treating patients with a DAA in a&#xD;
      community health clinic setting as compared to the standard-of-care subspecialty setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Actual">June 6, 2019</completion_date>
  <primary_completion_date type="Actual">June 6, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two parallel investigational groups in different community health clinic treatment settings assigned to treatment with elbasvir-grazoprevir as compared to an academic hepatology clinic retrospective cohort treated with elbasvir-grazoprevir.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR 12</measure>
    <time_frame>24 weeks post-initiation of treatment (12 weeks post-completion of treatment)</time_frame>
    <description>Sustained Viremic Response at 12 weeks post-completion of treatment. SVR12 was determined negative if undetectable (&lt;20 copies) by polymerase chain reaction and positive if EITHER loss-to-follow up and no lab data or virus was detected greater than 20 copies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVR 48</measure>
    <time_frame>60 weeks post-initiation of treatment (48 weeks post-completion of treatment)</time_frame>
    <description>Sustained Viremic Response at 48 weeks post-completion of treatment (SVR48). Participants &quot;Achieving SVR48&quot; had a negative hepatitis C real time polymerase chain reaction (RT-PCR) test at 48 weeks after end of treatment. Participants who &quot;Did Not Achieve SVR48&quot; had a positive hepatitis C RT-PCR test at 48 weeks after end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation Rate or Lost To Follow Up</measure>
    <time_frame>Study duration (60 weeks)</time_frame>
    <description>Percentage of patients discontinuing medications prior to completion of 12 weeks or being lost to follow up, defined as inability to reach patient after 3 attempts and patients not following up with primary endpoint labs (SVR 12, 48)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NS5A Resistance</measure>
    <time_frame>At Study Screening/Enrollment</time_frame>
    <description>Percentage of patients with genotype 1a and NS5A Resistance-Associated Variants (RAVs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>12 weeks (duration of treatment)</time_frame>
    <description>Adherence determined by client/subject self-reported medication adherence measured by percentage of pills taken on a monthly basis. Categorically separated into &lt; 90% adherence, 90-99% adherence, 100% adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection Drug Use Relapse (IDU)</measure>
    <time_frame>Duration of study (60 weeks)</time_frame>
    <description>Self reported relapse IDU following HCV treatment (MAT arm)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Substance Use Disorders</condition>
  <condition>Substance Abuse, Intravenous</condition>
  <arm_group>
    <arm_group_label>Old Town Clinic, Medication Assisted Therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Outside In Clinic, Needle Exchange Program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OHSU Hepatology Clinic, Academic center Retrospective Cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health &amp; Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elbasvir-grazoprevir (50 mg/100 mg)</intervention_name>
    <description>12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
    <arm_group_label>OHSU Hepatology Clinic, Academic center Retrospective Cohort</arm_group_label>
    <arm_group_label>Old Town Clinic, Medication Assisted Therapy group</arm_group_label>
    <arm_group_label>Outside In Clinic, Needle Exchange Program</arm_group_label>
    <other_name>Zepatier</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genotype 1b and genotype 1a without baseline NS5A resistance or Genotype 4&#xD;
&#xD;
          -  APRI Score &lt;0.7; if &gt;0.7 a Fibrosure/Fibrotest or Fibroscan score of F2 or less&#xD;
&#xD;
          -  No clinical or laboratory evidence of cirrhosis&#xD;
&#xD;
          -  Readiness for treatment based on ability to make &gt;2/3 sequential office visits&#xD;
&#xD;
          -  Patients must be assessed to have decision-making capacity, be capable of consenting,&#xD;
             and not be displaying evidence of overt intoxication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical or Laboratory Evidence of Cirrhosis&#xD;
&#xD;
          -  Elevated prothrombin time unrelated to anticoagulation, hemoglobin level less than&#xD;
             12.3 g/L in females and &lt;14 g/L in males, platelet count &lt;150 Ã— 109 cells/L), white&#xD;
             blood cells (WBC) &lt;4.0 x103/mm3 , aminotransferase levels more than 10 times the upper&#xD;
             limit of normal, or albumin level &lt;3.5 g/L.&#xD;
&#xD;
          -  Previous treatment for hepatitis C infection&#xD;
&#xD;
          -  Hepatocellular carcinoma&#xD;
&#xD;
          -  HIV or hepatitis B virus co-infection&#xD;
&#xD;
          -  Subjects taking medications that are contra-indicated to administer with Zepatier&#xD;
             including phenytoin, carbamazepine, rifampin, St. John's Wort, and cyclosporine AND&#xD;
             unable to change these medications to one without interactions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atif Zaman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Old Town Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outside In</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Islam MM, Topp L, Conigrave KM, White A, Reid SE, Grummett S, Haber PS, Day CA. Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. J Subst Abuse Treat. 2012 Dec;43(4):440-5. doi: 10.1016/j.jsat.2012.07.007. Epub 2012 Aug 29.</citation>
    <PMID>22938915</PMID>
  </reference>
  <results_reference>
    <citation>Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013 Aug;57 Suppl 2:S56-61. doi: 10.1093/cid/cit271. Review.</citation>
    <PMID>23884067</PMID>
  </results_reference>
  <results_reference>
    <citation>Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013 Aug;57 Suppl 2:S80-9. doi: 10.1093/cid/cit306. Review.</citation>
    <PMID>23884071</PMID>
  </results_reference>
  <results_reference>
    <citation>Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat. 2005 Oct;29(3):159-65.</citation>
    <PMID>16183464</PMID>
  </results_reference>
  <results_reference>
    <citation>Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, Gallagher L, Storms M, Raffa JD, DeVlaming S, Duncan F, Conway B. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010 Mar;22(3):270-7.</citation>
    <PMID>20425880</PMID>
  </results_reference>
  <results_reference>
    <citation>Newman AI, Beckstead S, Beking D, Finch S, Knorr T, Lynch C, MacKenzie M, Mayer D, Melles B, Shore R. Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre. Can J Gastroenterol. 2013 Apr;27(4):217-23.</citation>
    <PMID>23616960</PMID>
  </results_reference>
  <results_reference>
    <citation>Mason K, Dodd Z, Sockalingam S, Altenberg J, Meaney C, Millson P, Powis J. Beyond viral response: A prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support. Int J Drug Policy. 2015 Oct;26(10):1007-13. doi: 10.1016/j.drugpo.2015.04.012. Epub 2015 Apr 29.</citation>
    <PMID>26005037</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <results_first_submitted>August 31, 2020</results_first_submitted>
  <results_first_submitted_qc>October 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2020</results_first_posted>
  <disposition_first_submitted>June 4, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>October 19, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 12, 2020</disposition_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Andrew Seaman</investigator_full_name>
    <investigator_title>Co Investigator</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>People Who Inject Drugs</keyword>
  <keyword>PWID</keyword>
  <keyword>Medication Assisted Therapy</keyword>
  <keyword>MAT</keyword>
  <keyword>Needle Exchange Program</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Substance Abuse, Intravenous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Grazoprevir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All electronic data will be maintained encrypted in the Red Cap repository. Only the primary investigator and co-investigator will have access to the master spreadsheet linking study and personal identifiers. Andrew Seaman, co-investigator and primary study contact, will be listed as the repository guardian. He will be responsible for ensuring data are released according to OHSU policy and the institutional review board (IRB) approved repository protocol, executing a repository sharing agreement in case data are released for future research, ensuring the security and confidentiality of all stored data, ensuring the security and confidentiality of data, and tracking releases of data. The repository guardian will be responsible for verifying that future releases are done in concordance with pre-proposed limits and the original consent. Data transport at the time of any future IRB approved data sharing will be approved by an updated research services agreement and separate IRB approval.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03093415/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03093415/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants for the medication assisted therapy (MAT) group were all recruited and enrolled from within a single FQHC that provides office based opioid treatment with buprenorphine. Participants in the needle exchange program were similarly recruited in that setting. Retrospective comparison group was an academic hepatology referral clinic.</recruitment_details>
      <pre_assignment_details>This is a non-randomized, prospective cohort trial. No washout/run-in occured.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Old Town Clinic, Medication Assisted Therapy Group</title>
          <description>25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
        </group>
        <group group_id="P2">
          <title>Outside In Clinic, Needle Exchange Program</title>
          <description>25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
        </group>
        <group group_id="P3">
          <title>OHSU Hepatology Clinic, Academic Center Retrospective Cohort</title>
          <description>50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health &amp; Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Assessed for Eligibility --&gt; Enrollment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion Criteria: No MAT</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion Criteria: neg HCV</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion Criteria: No active use</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion Criteria: Fibrosis &gt; F2</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusion Criteria: HIV</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion Criteria: Wrong Genotype</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusion Criteria: NS5a Resistance</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusion Criteria: Treatment Readiness</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Lab exclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Enrollment to SVR12 Results</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25">Pre-specified 25 participants to were enrolled.</participants>
                <participants group_id="P2" count="25">Pre-specified 25 participants to were enrolled.</participants>
                <participants group_id="P3" count="50">Prespecified 50 participants enrolled.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All baseline characteristics were collected on both consented, prospective study groups (MOUD and Needle Exchange Program groups). The retrospective cohort only collected Age, Sex, Race/Ethnicity, Genotype, and APRI score and excluded level of education, duration of primary care establishment, and drug of choice.</population>
      <group_list>
        <group group_id="B1">
          <title>Old Town Clinic, Medication Assisted Therapy Group</title>
          <description>25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
        </group>
        <group group_id="B2">
          <title>Outside In Clinic, Needle Exchange Program</title>
          <description>25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
        </group>
        <group group_id="B3">
          <title>OHSU Hepatology Clinic, Academic Center Retrospective Cohort</title>
          <description>50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health &amp; Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="11.3"/>
                    <measurement group_id="B2" value="41" spread="11.9"/>
                    <measurement group_id="B3" value="60" spread="7.5"/>
                    <measurement group_id="B4" value="51" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black / African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latinx</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Highest Level of Education</title>
          <description>Includes 4 categories: Did not complete high school, high school completion, trade school completion, bachelors degree or higher</description>
          <population>*OHSU clinic did not collect education data for comparison based on study model</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Did not complete highschool</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High school completion</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Trade school completion</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bachelors degree or higher</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Income</title>
          <description>Baseline income as percent of federal poverty level</description>
          <population>*OHSU group did not collect baseline income data, as per study model</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0-50% Federal Poverty Level</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>51-100% Federal Poverty Level</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 101% Federal Poverty Level</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fibrosis Status</title>
          <description>Baseline fibrosis predictor based on aspartate aminotransferase to platelet ratio index (APRI) below or above 0.7. All candidates had EITHER APRI &lt; 0.7 OR non-invasive fibrosis score of F2 or below, by study inclusion data.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>APRI &lt; 0.7</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>APRI &gt; 0.7</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Genotype</title>
          <description>Eligible participants were Genotype 1a, b, Genotype 4</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Genotype 1a</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Genotype 1b</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Genotype 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Established in Primary Care</title>
          <description>Number of participants 1) Not established in primary care, 2) established &lt; 1 year, 3) established &gt; 1 year.</description>
          <population>*OHSU group did not collect this data per study design</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Not established in primary care</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Established in primary care &lt; 1 year</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Established in primary care &gt; 1 year</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Housing Status</title>
          <description>Participants were divided into either Houseless/Unstable housing (Unstable category included staying with family on short term conditional basis, couch surfing with an acquaintance, or other non-legally protected indoor housing arrangement) or Stable/Transitional housing.</description>
          <population>OHSU group did not collect housing data based on our study model.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Houseless / Unstable Housing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Transitional / Stable Housing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drug of choice</title>
          <description>Participants were asked to identify their drug of choice, given options Heroin, Methamphetamines, Alcohol, and Cannabis.</description>
          <population>OHSU did not collect drug use data, as per our study model.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Heroin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Methamphetamines</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alcohol</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cannabis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SVR 12</title>
        <description>Sustained Viremic Response at 12 weeks post-completion of treatment. SVR12 was determined negative if undetectable (&lt;20 copies) by polymerase chain reaction and positive if EITHER loss-to-follow up and no lab data or virus was detected greater than 20 copies.</description>
        <time_frame>24 weeks post-initiation of treatment (12 weeks post-completion of treatment)</time_frame>
        <population>All participants enrolled were analyzed using intention to treat (ITT) methodology for sustained viremic response at 12 weeks after end of treatment (SVR12).</population>
        <group_list>
          <group group_id="O1">
            <title>Old Town Clinic, Medication Assisted Therapy Group</title>
            <description>25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O2">
            <title>Outside In Clinic, Needle Exchange Program</title>
            <description>25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O3">
            <title>OHSU Hepatology Clinic, Academic Center Retrospective Cohort</title>
            <description>50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health &amp; Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>SVR 12</title>
          <description>Sustained Viremic Response at 12 weeks post-completion of treatment. SVR12 was determined negative if undetectable (&lt;20 copies) by polymerase chain reaction and positive if EITHER loss-to-follow up and no lab data or virus was detected greater than 20 copies.</description>
          <population>All participants enrolled were analyzed using intention to treat (ITT) methodology for sustained viremic response at 12 weeks after end of treatment (SVR12).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>SVR12 negative, intention to treat</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>SVR12 positive, intention to treat</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR 48</title>
        <description>Sustained Viremic Response at 48 weeks post-completion of treatment (SVR48). Participants &quot;Achieving SVR48&quot; had a negative hepatitis C real time polymerase chain reaction (RT-PCR) test at 48 weeks after end of treatment. Participants who &quot;Did Not Achieve SVR48&quot; had a positive hepatitis C RT-PCR test at 48 weeks after end of treatment.</description>
        <time_frame>60 weeks post-initiation of treatment (48 weeks post-completion of treatment)</time_frame>
        <population>Limitations in study funding and delayed recruitment prevented both prospective groups from collecting full SVR48 data. Therefore, PER PROTOCOL (PP) data presented below. Analysis framework for this secondary outcome was not pre-specified but PP analysis most appropriate given reasons for lacking data. OHSU comparison did not collect SVR48 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Town Clinic, Medication Assisted Therapy Group</title>
            <description>25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O2">
            <title>Outside In Clinic, Needle Exchange Program</title>
            <description>25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O3">
            <title>OHSU Hepatology Clinic, Academic Center Retrospective Cohort</title>
            <description>50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health &amp; Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>SVR 48</title>
          <description>Sustained Viremic Response at 48 weeks post-completion of treatment (SVR48). Participants &quot;Achieving SVR48&quot; had a negative hepatitis C real time polymerase chain reaction (RT-PCR) test at 48 weeks after end of treatment. Participants who &quot;Did Not Achieve SVR48&quot; had a positive hepatitis C RT-PCR test at 48 weeks after end of treatment.</description>
          <population>Limitations in study funding and delayed recruitment prevented both prospective groups from collecting full SVR48 data. Therefore, PER PROTOCOL (PP) data presented below. Analysis framework for this secondary outcome was not pre-specified but PP analysis most appropriate given reasons for lacking data. OHSU comparison did not collect SVR48 data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Achieved SVR48</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did Not Achieve SVR48</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Discontinuation Rate or Lost To Follow Up</title>
        <description>Percentage of patients discontinuing medications prior to completion of 12 weeks or being lost to follow up, defined as inability to reach patient after 3 attempts and patients not following up with primary endpoint labs (SVR 12, 48)</description>
        <time_frame>Study duration (60 weeks)</time_frame>
        <population>All participants analyzed for this variable</population>
        <group_list>
          <group group_id="O1">
            <title>Old Town Clinic, Medication Assisted Therapy Group</title>
            <description>25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O2">
            <title>Outside In Clinic, Needle Exchange Program</title>
            <description>25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O3">
            <title>OHSU Hepatology Clinic, Academic Center Retrospective Cohort</title>
            <description>50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health &amp; Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Discontinuation Rate or Lost To Follow Up</title>
          <description>Percentage of patients discontinuing medications prior to completion of 12 weeks or being lost to follow up, defined as inability to reach patient after 3 attempts and patients not following up with primary endpoint labs (SVR 12, 48)</description>
          <population>All participants analyzed for this variable</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Completed therapy and SVR12 lab confirmation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discontinued therapy, or incomplete SVR12 labs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NS5A Resistance</title>
        <description>Percentage of patients with genotype 1a and NS5A Resistance-Associated Variants (RAVs)</description>
        <time_frame>At Study Screening/Enrollment</time_frame>
        <population>165 potential participants in medication assisted therapy group and 135 potential participants in needle exchange group were analyzed for Non-Structural Protein 5a (NS5a) resistance. OHSU Hepatology cohort only included treated individuals and NS5a resistance data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Town Clinic, Medication Assisted Therapy Group</title>
            <description>25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O2">
            <title>Outside In Clinic, Needle Exchange Program</title>
            <description>25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O3">
            <title>OHSU Hepatology Clinic, Academic Center Retrospective Cohort</title>
            <description>50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health &amp; Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>NS5A Resistance</title>
          <description>Percentage of patients with genotype 1a and NS5A Resistance-Associated Variants (RAVs)</description>
          <population>165 potential participants in medication assisted therapy group and 135 potential participants in needle exchange group were analyzed for Non-Structural Protein 5a (NS5a) resistance. OHSU Hepatology cohort only included treated individuals and NS5a resistance data were not collected.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NS5a Resistance to Elbasvir-Grazoprevir Detected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NS5a Resistance to Elbasvir-Grazoprevir Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Adherence</title>
        <description>Adherence determined by client/subject self-reported medication adherence measured by percentage of pills taken on a monthly basis. Categorically separated into &lt; 90% adherence, 90-99% adherence, 100% adherence.</description>
        <time_frame>12 weeks (duration of treatment)</time_frame>
        <population>Enrolled study participants in prospective arms initiating therapy. Self report combined will pharmacist pill count adherence data assessed by study pharmacist at q4week study visits, including end of treatment. Retrospective comparison group at OHSU did not collect adherence data.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Town Clinic, Medication Assisted Therapy Group</title>
            <description>25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O2">
            <title>Outside In Clinic, Needle Exchange Program</title>
            <description>25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O3">
            <title>OHSU Hepatology Clinic, Academic Center Retrospective Cohort</title>
            <description>50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health &amp; Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Adherence</title>
          <description>Adherence determined by client/subject self-reported medication adherence measured by percentage of pills taken on a monthly basis. Categorically separated into &lt; 90% adherence, 90-99% adherence, 100% adherence.</description>
          <population>Enrolled study participants in prospective arms initiating therapy. Self report combined will pharmacist pill count adherence data assessed by study pharmacist at q4week study visits, including end of treatment. Retrospective comparison group at OHSU did not collect adherence data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Less than 90% Adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>90 - 99% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>100% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Injection Drug Use Relapse (IDU)</title>
        <description>Self reported relapse IDU following HCV treatment (MAT arm)</description>
        <time_frame>Duration of study (60 weeks)</time_frame>
        <population>These data were not collected. The study group determined that the definition of &quot;relapse&quot; was inappropriate for the study population given the nature of ongoing use in the MAT group and the lack of comparison with the outside in group, that was currently using drugs by definition. Scientific value of these data was thought to be limited.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Town Clinic, Medication Assisted Therapy Group</title>
            <description>25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O2">
            <title>Outside In Clinic, Needle Exchange Program</title>
            <description>25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
          <group group_id="O3">
            <title>OHSU Hepatology Clinic, Academic Center Retrospective Cohort</title>
            <description>50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health &amp; Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Injection Drug Use Relapse (IDU)</title>
          <description>Self reported relapse IDU following HCV treatment (MAT arm)</description>
          <population>These data were not collected. The study group determined that the definition of &quot;relapse&quot; was inappropriate for the study population given the nature of ongoing use in the MAT group and the lack of comparison with the outside in group, that was currently using drugs by definition. Scientific value of these data was thought to be limited.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Between study enrollment and SVR12 = 24 weeks</time_frame>
      <desc>Reporting mirrors clinicaltrials.gov definitions. All-Cause Mortality and Other [Not Including Serious] Adverse Events were not monitored/assessed for the OHSU Hepatology Clinic, Academic Center Retrospective Cohort. All serious and other adverse effects were monitored for the two prospective arms, as reported below.</desc>
      <group_list>
        <group group_id="E1">
          <title>Old Town Clinic, Medication Assisted Therapy Group</title>
          <description>25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
        </group>
        <group group_id="E2">
          <title>Outside In Clinic, Needle Exchange Program</title>
          <description>25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
        </group>
        <group group_id="E3">
          <title>OHSU Hepatology Clinic, Academic Center Retrospective Cohort</title>
          <description>50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health &amp; Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.&#xD;
elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective Endocarditis</sub_title>
                <description>One participant developed infectious endocarditis as a complication of active injection drug use during the study period in the MAT arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Mild, self limiting</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Mild headache, did not discontinue therapy, self-limited</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Mild, self-limited, did not lead to discontinuation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Mild, self-limited, did not lead to discontinuation</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Mild, self-limited, did not lead to discontinuation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study groups comparisons of sites of enrollment/treatment (MAT clinic vs needle exchange) rather than disease state (many MAT participants used needle exchange; many needle exchange on MAT); funding limitations prevented SVR48 collection.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Andrew Seaman, MD</name_or_title>
      <organization>Oregon Health and Sciences University</organization>
      <phone>1 (971) 271 - 6102</phone>
      <email>seaman@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

